4 May 2026 UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers read more
4 May 2026 Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB read more
1 May 2026 Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares read more
14 April 2026 Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline read more
9 January 2026 Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets read more
